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Granulocyte colony-stimulating factor (G-CSF) regu-
lates neutrophil production through activation of its
cognate receptor, the G-CSF-R. Previous studies with
deletion mutants have shown that the membrane-prox-
imal cytoplasmic domain of the receptor is sufficient for
mitogenic signaling, whereas the membrane-distal do-
main is required for differentiation signaling. However,
the function of the four cytoplasmic tyrosines of the
G-CSF-R in the control of proliferation, differentiation,
and survival has remained unclear. Here we investi-
gated the role of these tyrosines by expressing a tyrosine
“null” mutant and single tyrosine “add back” mutants in
maturation-competent myeloid 32D cells. Clones ex-
pressing the null mutant showed only minimal prolifer-
ation and differentiation, with survival also reduced at
low G-CSF concentrations. Analysis of clones expressing
the add-back mutants revealed that multiple tyrosines
contribute to proliferation, differentiation, and survival
signals from the G-CSF-R. Analysis of signaling path-
ways downstream of these tyrosines suggested a posi-
tive role for STAT3 activation in both differentiation
and survival signaling, whereas SHP-2, Grb2 and Shc
appear important for proliferation signaling. In addi-
tion, we show that a tyrosine-independent “differentia-
tion domain” in the membrane-distal region of the G-
CSF-R appears necessary but not sufficient for
mediating neutrophilic differentiation in these cells.
The production of blood cells is regulated by a range of
extracellular stimuli, including a network of hematopoietic
growth factors and cytokines. One of these, granulocyte colony-
stimulating factor (G-CSF),1 is a major regulator of neutro-
philic granulocyte production and augments the proliferation,
survival, maturation, and functional activation of cells of the
granulocytic lineage (1–4). The actions of G-CSF are mediated
through its interaction with a specific cell surface receptor, the
G-CSF-R, which forms homo-oligomeric complexes upon ligand
binding (5). Typical of other members of the hematopoietin
receptor superfamily, the G-CSF-R has no intrinsic tyrosine
kinase activity but activates cytoplasmic tyrosine kinases (2, 5,
6). Important signaling molecules utilized by the G-CSF-R
include the Janus tyrosine kinases Jak1, Jak2, and Tyk2 (7–
10), the Src kinases p55lyn and p56/59hck (11–13), the signal
transducer and activator of transcription (STAT) proteins
STAT1, STAT3, and STAT5 (9, 14–19), and components of
the p21ras/Raf/mitogen-activated protein kinase pathway
(8, 20–24).
The cytoplasmic region of the G-CSF-R can be subdivided
into a membrane-proximal domain, which contains two con-
served subdomains known as box 1 and box 2, and a mem-
brane-distal domain, which contains a less-conserved box 3
sequence (5). In myeloid cells, the membrane-proximal domain
is essential for mitogenic signaling, whereas the membrane-
distal domain is essential for the transduction of differentiation
signals (19, 25–27). In addition, there are four tyrosine (Tyr)
residues in the cytoplasmic region of the G-CSF-R, at positions
704, 729, 744, and 764 of the human receptor, three of which lie
in the membrane-distal domain (28). Ligation of the G-CSF-R
results in the rapid phosphorylation of these four tyrosines (7,
29), which form potential binding sites for signaling molecules
that contain Src homology 2 (SH2) or phosphotyrosine binding
domains (30, 31). Some signaling pathways emanating from
the different tyrosines of the G-CSF-R have been identified. For
example, we and others have shown that Tyr-704 and Tyr-744
of the G-CSF-R are involved in the recruitment and activation
of STAT3 by the G-CSF-R (15, 17, 18, 32). In addition, Tyr-764
is necessary for the formation of Shc/Grb2/p140 complexes as
well as the activation of p21ras (22, 33). However, studies to
determine the role of each of the four cytoplasmic tyrosines in
mediating the effects of G-CSF on proliferation, differentiation,
and survival have yielded ambiguous and somewhat conflicting
results (15, 17, 21, 22, 29, 33, 34).
To better define the role of receptor tyrosines in signaling
from the G-CSF-R, we examined the ability of a tyrosine null
mutant and a series of single tyrosine add back mutants to
transduce biological signals in response to G-CSF. Further-
more, we performed these studies in maturation-competent
myeloid 32D cells, which are able to closely recapitulate many
of the cellular responses to G-CSF, including proliferation,
survival, and, importantly, terminal differentiation into ma-
ture neutrophils (27). Thus, 32D cells provide an appropriate
cellular context to assess the physiological relevance of signals
from the G-CSF-R. This analysis revealed that multiple ty-
rosines contribute to proliferation, differentiation, and survival
signaling from the human G-CSF-R. Analysis of signaling
pathways downstream from these tyrosines suggest a positive
role for STAT3 activation in both differentiation and survival,
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whereas SHP-2, Grb2, and Shc appear important for prolifer-
ation. In addition, we show that a tyrosine-independent “dif-
ferentiation domain” in the membrane-distal region of the G-
CSF-R appears necessary, although not sufficient, for
mediating neutrophilic differentiation in 32D cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection of G-CSF-R Constructs—The pLNCX
expression constructs of human G-CSF-R wild-type (WT), a series of
triple Tyr3 Phe add back mutants (mA, mB, mC, and mD), a quadru-
ple Tyr3 Phe null mutant (mO), and a truncation mutant derived from
a patient with severe congenital neutropenia (mDA) have been de-
scribed previously (18, 27). A subline of the IL-3-dependent murine
myeloid cell line 32D.cl3, called 32D.cl8.6, which lacked endogenous
G-CSF-R expression but remained maturation-competent, was gener-
ated as described previously (27). This was maintained in RPMI 1640
medium supplemented with 10% fetal calf serum and 10 ng/ml murine
IL-3. The expression constructs were linearized by PvuI digestion and
transfected into 32D.cl8.6 cells by electroporation. After 48 h of incu-
bation, cells were selected with G418 (Life Technologies, Inc.) at a
concentration of 0.8 mg/ml. Multiple clones were expanded for further
analysis. To check G-CSF-R expression levels, cells were incubated at
room temperature for 60 min with 10 mg/ml biotinylated mouse anti-
human G-CSF-R monoclonal antibody LMM741 (PharMingen, San
Diego, CA), then at 4 °C for 60 min sequentially with 5 mg/ml
phycoerythrin-conjugated streptavidin, 5 mg/ml biotinylated anti-
streptavidin antibody, and finally 2 mg/ml phycoerythrin-conjugated
streptavidin, with washing between each antibody step. Samples were
analyzed by flow cytometry using a FACScan (Becton Dickinson, San
Jose, CA). Several independently derived cell lines of each construct
were selected on the basis of equivalent receptor expression.
Cell Proliferation and Morphological Analysis—To determine the
proliferation and differentiation characteristics of 32D.cl8.6 clones,
cells were incubated at an initial density of 1–2 3 105 cells/ml in RPMI
medium supplemented with 10% fetal calf serum and either 100 ng/ml
human G-CSF, 10 ng/ml of murine IL-3, or without growth factors. The
medium was replenished every 1–2 days, and the cell densities were
adjusted to 1–2 3 105 cells/ml. Viable cells were counted on the basis of
trypan blue exclusion. To analyze the morphological features, cells were
spun onto glass slides and examined by May-Gru¨nwald-Giemsa stain-
ing. To quantify the neutrophilic maturation of 32D.cl8.6 transfectants
in response to G-CSF, the number of terminally differentiated cells was
determined and expressed as a percentage of total living cells
(% neutrophils).
Preparation of Cell Lysates and Western Blotting—Cells were de-
prived of serum and factors for 4 h at 37 °C in RPMI 1640 medium at a
density of 1 3 106/ml and then stimulated with either RPMI 1640
medium alone or in the presence of 100 ng/ml human G-CSF. At
different time points, 10 volumes of ice-cold phosphate-buffered saline
supplemented with 10 mM Na3VO4 were added. Subsequently, cells
were pelleted and lysed by incubation for 30 min at 4 °C in Tyr(P) lysis
buffer (1% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.1 mM
FIG. 1. Expression of G-CSF-R mu-
tants in myeloid 32D cells. A, sche-
matic diagram of the cytoplasmic do-
mains of mutant G-CSF-R proteins. Boxes
1, 2, and 3 denote subdomains conserved
in several members of the hematopoietin
receptor superfamily (5). B, flow cytomet-
ric analysis of G-CSF-R expression on pa-
rental 32D.cl8.6 cells (par) or transfec-
tants. Cells were either stained with
biotinylated mouse anti-human G-CSF-R
antibodies followed by phycoerythrin-con-
jugated streptavidin, biotinylated anti-
streptavidin, and finally phycoerythrin-
conjugated streptavidin (unfilled) or with-
out the anti-G-CSF-R step (filled) and an-
alyzed for fluorescence (FL2-Height).
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Na3VO4, 1 mM dithiothreitol, 1 mM Pefabloc SC, 50 mg/ml aprotinin, 50
mg/ml leupeptin, 50 mg/ml bacitracin) followed by centrifugation at
13,000 3 g for 15 min. The soluble proteins were mixed with sample
buffer, separated by SDS-polyacrylamide gel electrophoresis (SDS-poly-
acrylamide gel electrophoresis), and transferred onto nitrocellulose (0.2
mm; Schleicher & Schuell). Filters were blocked by incubation in TBST
(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% (v/v) Tween 20) contain-
ing 0.6% (w/v) bovine serum albumin. Antibodies used for Western
blotting were anti-phospho-STAT3[Y705] (New England Biolabs, Inc.
Beverly, MA), anti-phospho-STAT3[S727] (New England Biolabs), and
anti-STAT3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and were
diluted in TBST containing 0.6% (w/v) bovine serum albumin. After
washing with TBST, immune complexes were detected with horserad-
ish peroxidase-conjugated species-specific antiserum (DAKO, Glostrup,
Denmark) followed by enhanced chemiluminescence reaction (DuPont).
In some instances, membranes were stripped in 62.5 mM Tris-HCl, pH
6.7, 2% SDS, and 100 mM b-mercaptoethanol at 50 °C for 30 min,
reblocked, washed, and reprobed.
Far Western Analysis—The cytoplasmic domain of the human G-
CSF-R was cloned into pET-15b (Novagen, Madison, WI) as described
(18). In addition, the following glutathione S-transferase fusion con-
structs were made utilizing standard polymerase chain reaction proto-
cols to amplify the appropriate coding regions, which were cloned into
pGEX-2T (Amersham Pharmacia Biotech): Grb2-FL (SH3-SH2-SH3),
Grb2-FL(mut) (SH3-SH2mutant-SH3), Shc-SH2, SHP-1-SH2(N), SHP-
1-SH2(C), SHP-2-SH2(N), SHP-2-SH2(C), Syk-SH2(N), and Syk-
SH2(C). The authenticity of all constructs was verified by DNA se-
quencing. In addition, constructs were obtained for the production of
glutathione S-transferase fusions with GAP-SH2(N) and GAP-SH2(C)
from Tony Pawson, Vav-SH2 and Fps-SH2 from Lewis Cantley, CrkL-
SH2 and Abl-SH2 from Wallace Langdon, and Grb14-SH2 from Roger
Daly. For the production of tyrosine-phosphorylated G-CSF-R cytoplas-
mic domain, the pET clone was introduced into the E. coli strain TKB1
(Stratagene, La Jolla, CA), which contains an inducible tyrosine kinase.
Fusion protein was produced and purified according to the manufactur-
er’s instructions, then 32P-labeled using heart muscle kinase. For the
production of glutathione S-transferase fusions, plasmids were trans-
formed into XL-1 Blue (Stratagene), with proteins expressed and puri-
fied on glutathione-Sepharose 4B beads as described (35). These pro-
teins were then electrophoresed on 10% SDS-polyacrylamide gel
electrophoresis gels (36) and electrophoretically transferred to Hy-
bond-C membranes (Amersham Pharmacia Biotech). The membranes
were processed through a denaturation-renaturation cycle (37) and
probed with the 32P-labeled G-CSF-R, as described (38).
RESULTS
Expression of G-CSF-R Mutants in Maturation-competent
32D Cells—The contribution of receptor tyrosines to G-CSF-R
function has remained unclear (15, 17, 21, 22, 29, 33, 34).
Therefore, to better understand the role of these tyrosines, we
analyzed a quadruple Tyr 3 Phe or null mutant with no
cytoplasmic tyrosines (mO) and a series of triple Tyr3 Phe or
add back mutants, which each retain a single cytoplasmic
tyrosine (mA, mB, mC, and mD). Expression vectors encoding
these mutant receptors along with WT and truncated (mDA)
G-CSF-Rs (Fig. 1A) were introduced into a subline of the IL-3-
dependent murine myeloid cell line 32D.cl3 called 32D.cl8.6
that does not express endogenous G-CSF-R. Surface expression
of the G-CSF-R was determined using fluorescence-activated
cell sorter analysis, and cell lines expressing equivalent levels
of receptor were selected for further analysis, with at least
three independent clones studied for each construct. Examples
of clones expressing WT or mutant G-CSF-R proteins are
shown in Fig. 1B.
Receptor Tyrosines Are Required for Proliferation and Differ-
entiation but Are Dispensable for Survival at High Ligand
Concentration—To ascertain whether receptor tyrosines were
required at all to mediate proliferation, survival, and differen-
tiation responses in response to G-CSF in 32D cells, we first
compared the WT and tyrosine null mutant (mO) G-CSF-Rs. To
this end, 32D[WT] and 32D[mO] transfectants were switched
from IL-3- to G-CSF-containing medium following extensive
washing to remove any traces of IL-3. In the absence of IL-3 or
G-CSF, all transfectants died within 1 to 2 days without show-
ing any signs of differentiation. However, in response to 100
ng/ml G-CSF, 32D[WT] cells showed transient proliferation for
5 to 7 days (Fig. 2). After 6 to 10 days, 32D[WT] cells developed
into terminally differentiated neutrophils, as shown by an in-
creased cytoplasm-to-nucleus ratio, a neutrophilic granule-con-
taining cytoplasm, and lobulated nuclei (Fig. 3, A and B). In
contrast, 32D[mO] cells showed only minimal proliferation and
differentiation in response to G-CSF, although cell viability
was largely maintained at this saturating ligand concentration
(Figs. 2 and 3). This result establishes that receptor tyrosines
are required to facilitate proliferation and differentiation re-
sponses from the full-length G-CSF-R.
Multiple Tyrosines Contribute to Proliferation and Differen-
tiation Signaling—The almost complete abrogation of prolifer-
ation and differentiation signaling from the tyrosine null mu-
tant receptor provided the opportunity to determine the
contribution of individual tyrosines to these pathways through
the analysis of clones expressing the tyrosine add back mutants
(Figs. 2 and 3). This revealed that Tyr-704 alone (mA) could
contribute to both G-CSF-mediated proliferation and differen-
tiation signaling. This mutant elicited initial proliferation re-
sponses equivalent to those from the wild-type receptor, al-
though the proliferative phase terminated slightly earlier.
Concurrently, mA produced an earlier and more complete dif-
ferentiation compared with the WT receptor. In contrast, Tyr-
729 (mB) gave only a very weak signal for differentiation, with
no significant increase in proliferation compared with the null
mutant. The Tyr-744-containing mutant (mC) produced a phe-
notype similar to the Tyr-704-containing mA, although with
slightly less proliferation and differentiation. Finally, analysis
of 32D[mD] cells revealed that Tyr-764 projects strong prolif-
erative signals, such that these cells continued to proliferate
indefinitely on G-CSF, with no significant differentiation
observed.
The Membrane-distal Region of the Human G-CSF-R Con-
tains a Tyrosine-independent Differentiation Domain Essential
for Neutrophilic Differentiation in 32D Cells—We had previ-
ously identified the membrane-distal domain of the G-CSF-R
as essential for the transduction of differentiation signals
based on the observation that a truncation mutant isolated
from a patient with severe congenital neutropenia, mDA, which
lacks this domain, was unable to elicit differentiation in mye-
loid cells (19, 25–27). The construction of mutant mA, which
lacks all three tyrosines in this domain, allowed an assessment
FIG. 2. Proliferation of 32D clones in response to G-CSF. Cell-
proliferation of 32D.cl8.6 clones expressing WT or mutant G-CSF-Rs, as
indicated, in response to 100 ng/ml G-CSF. Data represent the mean
growth of three independent clones for each receptor construct. f, WT;
, mA; L, mB; E; mC; , mD; M, mO; Y, mDA.
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of whether tyrosines were required for these effects. Compari-
son of the 32D[mA] and 32D[mDA] clones revealed that the
membrane-distal domain lacking all tyrosines still augments
differentiation (Figs. 2 and 3).
Signals for Survival at Low Ligand Concentration Parallel
Those for Differentiation—We have shown above that 32D[mO]
cells are largely able to survive at 100 ng/ml G-CSF, without
undergoing significant proliferation. In contrast, survival at
lower G-CSF concentrations was impaired relative to 32D[WT]
cells, such that 32D[WT] cells can survive on 0.1 ng/ml G-CSF,
whereas 32D[mO] cells cannot (Fig. 4). We could then deter-
mine the contribution of individual tyrosines to this low dose
G-CSF-mediated survival signaling by exposing clones to dif-
ferent concentrations of ligand. Results with the add-back mu-
tants showed a strong role for Tyr-704 and Tyr-744 and a weak
role for Tyr-729 in mediating survival, with Tyr-764 apparently
having no role. This clearly parallels the effects of these ty-
rosines in mediating differentiation signals.
STAT3 Activation Correlates with Both Survival at Low Li-
gand Concentration and Differentiation—The concordant pat-
tern of survival at low doses of G-CSF and differentiation
resembled that for STAT3 activation from the G-CSF-R, which
we have recently reported in Ba/F3 cells (18). In the various
32D cells clones, G-CSF-mediated STAT3 activation, as meas-
ured by both tyrosine and serine phosphorylation, was greatest
with mA (Tyr-704) and mC (Tyr-744), with a lesser contribu-
tion from mB (Tyr-729) (Fig. 5). In contrast, mO was only
weakly able to activate STAT3, whereas mD (Tyr-764) showed
no more activation than mO. Thus, the ability of mutants to
activate STAT3 showed a striking correlation with the strength
of their respective differentiation and survival signals, suggest-
ing a positive role for STAT3 in the control of both processes.
FIG. 3. Neutrophilic differentiation
of 32D.cl8.6 transfectants in response
to G-CSF. A, morphological features of
32D[WT] cells in the presence of IL-3 or
representative clones expressing wild-
type or mutant G-CSF-R after 7 days
of exposure to G-CSF. B, maturation of
32D.cl8.6 cells expressing wild-type
or mutant G-CSF-Rs, as indicated, ex-
pressed as the percentage of living cells
showing terminal differentiation (% neu-
trophils) at each time point. Data repre-
sent the mean of three independent
clones of each. f, WT; , mA; L, mB; E;
mC; , mD; M, mO; T, mDA.
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Identification of Pathways Important for Proliferative Re-
sponses from the G-CSF-R—Finally, we also sought to identify
which signaling molecules might play a role in the tyrosine-
mediated proliferation signaling from the G-CSF-R, i.e. via
Tyr-704, Tyr-744, and Tyr-764. To achieve this we employed a
novel strategy to identify SH2 domains that could interact
directly with the phosphorylated tyrosines of the G-CSF-R. As
an initial screen, we used a 32P-labeled, tyrosine-phosphoryl-
ated WT G-CSF-R cytoplasmic domain simulating an activated
receptor to probe a range of SH2 domains immobilized on
nitrocellulose (Fig. 6A). This showed that the isolated SH2
domains of SHP-2 and Shc could bind to the receptor. In addi-
tion, full-length Grb2 could bind to the receptor, whereas a
specific SH2 domain mutant of Grb2 could not, implying that
the Grb2 SH2 domain also interacts directly with the G-CSF-R.
We were next able to map the specific tyrosine binding site(s) of
these SH2 domains by probing them with tyrosine-phosphoryl-
ated receptor proteins generated from the single tyrosine add-
back mutants (Fig. 6B). This revealed direct binding of SHP-2,
preferentially via its N-terminal SH2 domain, to both Tyr-704
and Tyr-764, and Grb2 and Shc via their respective SH2 do-
mains to Tyr-764. Because these tyrosines also elicit strong
proliferation signals, we can posit a direct role for SHP-2, Grb2,
and Shc in mediating these responses. No interactions of these
molecules with Tyr-744 were identified.
DISCUSSION
Previous studies to determine the role(s) of the cytoplasmic
tyrosines of the G-CSF-R in eliciting cellular responses have
been performed with deletion and single tyrosine substitution
mutants. These studies have yielded ambiguous results. This is
likely due, at least in part, to the use of inappropriate cell
models, which are unable to recapitulate the complete gamut of
G-CSF responses (15, 17, 21, 22, 29, 34). Furthermore, use of
truncation mutants to make inferences about tyrosine-specific
effects (17, 21, 34) is also problematic because of altered recep-
tor trafficking of such mutants (19, 39). Analysis of single Tyr
3 Phe substitution mutants has provided some insight into the
function of the receptor tyrosines, although even here the re-
sults are somewhat conflicting, implicating Tyr-44 and, to a
lesser extent, Tyr-704 and Tyr-729 in the macrophage differ-
entiation of M1 cells (15), Tyr-703 or Tyr-728 of the murine
G-CSF-R (equivalent to Tyr-704 and Tyr-729 of the human
receptor) in the neutrophilic differentiation of L-GM-1 cells
(29), and Tyr-764 in the proliferative responses of 32D cells
(33). However, a major problem with these studies is that they
may fail to reveal redundant pathways emanating from these
tyrosines.
Analysis of tyrosine null and add-back mutants has provided
a useful approach to investigate the complex roles of individual
cytoplasmic tyrosine residues in cytokine receptor signaling
(40, 41). Therefore, we used this approach to delineate the
function of tyrosine-mediated pathways from the G-CSF-R. In
addition, we chose a cell system, myeloid 32D cells, which most
closely mimics in vivo differentiation, because these cells are
able to differentiate from blast-like cells into mature neutro-
phils. The results of this analysis revealed multiple signals
emanating from the receptor tyrosines to control proliferation,
differentiation, and survival (Fig. 7). In addition, these studies
show that signals independent of receptor tyrosines also con-
tribute to differentiation and survival.
We found that signals from the G-CSF-R for both survival at
low G-CSF concentration and differentiation largely over-
lapped, being mediated most strongly by Tyr-704 and Tyr-744,
with a lesser contribution from Tyr-729. This showed a close
correlation with the ability of these tyrosines to activate STAT3
in these cells. The involvement of STAT3 in G-CSF-mediated
granulocytic differentiation is consistent with a recent study
showing that expression of dominant-negative STAT3 could
totally block this process (42). However, our data also suggest
that STAT3 activation may represent the key pathway in mat-
uration signaling from the full-length G-CSF-R. Furthermore,
we provide evidence suggestive of a role for STAT3 in G-CSF-
dependent survival signaling, as has also been postulated for
the related gp130 receptor component (43). However, it is clear
FIG. 4. Survival signaling from G-CSF-R tyrosine mutants. Cell
proliferation/survival analysis of 32D clones expressing the indicated
G-CSF-Rs performed as described in Fig. 2, except at 100 (f), 10 (E), 1
(), and 0.1 (L) ng/ml G-CSF.
FIG. 5. STAT3 activation by G-CSF-R
tyrosine mutants. Western blot analysis of
total lysates from 32D cells expressing wild-
type or mutant G-CSF-Rs, either starved (2)
or stimulated with G-CSF for 10 min (1),
probed with the antibodies indicated. pY,
Tyr(P); pS, Ser(P); C-term, C terminus.
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that, at high G-CSF concentrations, tyrosine-independent sur-
vival mechanisms also operate, potentially involving phos-
phatidylinositol 3-kinase (34) or mitogen-activated protein ki-
nase (21). Finally, there appears to be subtle differences in
G-CSF-mediated STAT3 activation in 32D cells compared with
that we have reported in Ba/F3 cells (18), such that the contri-
bution of tyrosine-independent STAT3 activation is less impor-
tant, whereas the Tyr-729-mediated route represents a novel
pathway of STAT3 activation in 32D cells. The reason for these
cell-specific differences remains unclear.
Proliferation signaling from the G-CSF-R was predomi-
nantly mediated via Tyr-704 and Tyr-764, with a minor contri-
bution from Tyr-744. We have previously reported formation of
Grb2/SHP-2, Grb2/p90, and Grb2/Shc/p140 complexes in re-
sponse to G-CSF, the latter two being dependent on Tyr-764
(22). Using in vitro binding studies, we show that Tyr-704 is a
direct docking site for SHP-2, whereas Tyr-764 is a direct
docking site for SHP-2, Grb2, and Shc, largely consistent with
the published consensus binding sites for these molecules (44,
45). In addition, we and others have shown that Grb2 interacts
with SHP-2 and Shc via binding of its SH2 domain with phos-
phorylated tyrosines in the SHP-2 C terminus (24, 46) and at
position 317 of Shc (31), respectively. Thus, there appears to be
at least four mechanisms by which Grb2 can interact with the
activated G-CSF-R: directly via Tyr-764 (complexed with p90?)
or indirectly via SHP-2 at Tyr-704 and Tyr-764 or Shc at
Tyr-764. The relative role of these alternate complexes in me-
diating G-CSF responses remains an important consideration
for future investigations. However, because SHP-2, Grb2, and
Shc have all been implicated in proliferation (31, 47–50), it
seems likely that these are the molecules responsible for the
proliferative signals emanating from Tyr-704 and Tyr-764. The
molecule(s) docking to Tyr-744, which mediate its weak prolif-
eration signal remain to be elucidated.
We have previously identified the membrane-distal domain
of the G-CSF-R as being essential for the transduction of dif-
ferentiation signals (19, 25–27). Analysis of the 32D[mA] clones
in this study has revealed that the membrane-distal domain is
required for differentiation independent of receptor tyrosines
(Figs. 2 and 3). However, because the 32D[mO] clones differ-
entiated poorly, we can presume that this domain alone is
FIG. 6. Far Western analysis of SH2-domains with recombinant
tyrosine-phosphorylated G-CSF-R. A, glutathione S-transferase (GST)
fusions of various SH2 domain-containing signaling molecules were sepa-
rated on replicate SDS-polyacrylamide gel electrophoresis gels and either
stained with Coomassie or transferred to nitrocellulose for Far Western
analysis with 32P-labeled, tyrosine-phosphorylated (Tyr(P)) WT G-CSF-R
cytoplasmic domain as a probe. B, far Western as described in A, except
using as probes 32P-labeled, tyrosine-phosphorylated cytoplasmic domains
from WT or mutant G-CSF-Rs, as indicated.
FIG. 7. Model for signaling from the
G-CSF-R leading to specific cellular
responses. Potential tyrosine-dependent
pathways leading to proliferation, differ-
entiation, and survival are indicated. In
addition, it is obvious that tyrosine-inde-
pendent pathways also contribute to
these processes, although the mecha-
nism(s) remain unclear.
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insufficient to induce complete maturation but rather co-oper-
ates with additional tyrosine-dependent signals (such as from
Tyr-704 or Tyr-744). We have recently shown that this region is
important for receptor internalization and concomitant deacti-
vation (19). Therefore, it is likely that a major function of this
tyrosine-independent differentiation domain is to negatively
regulate proliferation. Consistent with this, mD, which con-
tains this domain, elicits sustained proliferation but at a re-
duced rate compared with mDA, which does not. In addition,
the minor activation of STAT3 by this domain could also con-
tribute to its differentiation-inducing function.
The data presented here has unequivocally assigned specific
roles to the tyrosines of the G-CSF-R in mediating differentia-
tion, proliferation, and survival in a myeloid system capable of
full neutrophilic differentiation. We have shown that the four
tyrosines of the G-CSF-R possess distinct, yet overlapping,
functions. This is a similar conclusion to that obtained from
recent studies with other cytokine receptors, such as the eryth-
ropoietin receptor (41) and the common b-chain of the granu-
locyte-macrophage colony-stimulating factor receptor (40).
Having now identified the key intracellular mediators down-
stream of the receptor tyrosines, future studies will aim to
identify the targets of these molecules in eliciting the various
G-CSF-mediated biological responses.
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